E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
adult patients with imatinib - resistant or - intolerant CML-CP, CML-AP or CML-BC |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To provide patients with life threatening conditions: imatinib resistant/intolerant chronic myeloid leukemia - in blast crisis, accelerated phase and chronic phase, who have been previously enrolled in to CAMN107A2109 and benefit from the treatment, with access to nilotinib (AMN107) in Hungary until such time as the drug is financed by the National Health Insurance Fund in Hungary or for a period of 12 months, whichever comes first.
|
|
E.2.2 | Secondary objectives of the trial |
2. To collect additional safety and efficacy data on nilotinib (AMN107) in a population of the patients who will continue the treatment with nilotinib in Hungary after completion of the CAMN107A2109 trial.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients under consideration for participation in this study must meet the following inclusion criteria: 1. Imatinib - resistant or - intolerant Philadelphia chromosome-positive CML in chronic phase, accelerated phase or in blast crisis patients previously enrolled to CAMN107A2109 in Hungary and continuing the treatment with nilotinib at the time of enrollment for this trial. 2. According to the opinion of the investigators the patient would benefit from the further treatment with nilotinib. 3. No evidence of extramedullary leukaemic involvement, with the exception of liver and spleen. 4. Males or females ≥18 years of age. 5. QTc ≤ 450 msec on the average of three serial baseline ECG (using the QTcF formula). 6. Patients must have the following laboratory values: • Potassium within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication. • Total calcium (corrected for serum albumin) within normal limits or correctable with supplements. • Magnesium within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication. • Phosphorus ≥ LLN or correctable with supplements. • ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN unless considered due to tumour. • Alkaline phosphatase ≤ 2.5 x ULN unless considered due to tumour. • Serum bilirubin ≤ 1.5 x ULN unless considered due to tumour. • Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min. • Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN. 9. Written signed and dated informed consent prior to any study procedures being performed.
|
|
E.4 | Principal exclusion criteria |
1. Known T315I mutations 2. Impaired cardiac function including any one of the following: • LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by echocardiogram. • Inability to determine the QT interval on ECG. • Complete left bundle branch block. • Use of a ventricular-paced pacemaker. • Congenital long QT syndrome or a known family history of long QT syndrome. • History of or presence of clinically significant ventricular or atrial tachyarrhythmias. • Clinically significant resting brachycardia (< 50 beats per minute). • QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula). If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc. • History of clinically documented myocardial infarction. • History of unstable angina (during the last 12 months). • Other clinically significant heart disease (e.g. congestive heart failure or uncontrolled hypertension). 3. Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required) 4. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection) 5. History of significant congenital or acquired bleeding disorder unrelated to cancer 6. Previous radiotherapy to ≥ 25% of the bone marrow 7. Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery 8. History of non-compliance to medical regimens or inability to grant consent 9. Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon) 10. Patients actively receiving therapy with strong CYP3A4 inhibitors (e.g, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm. 11. Patients actively receiving therapy with strong CYP3A4 inducers (e.g, dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John’s Wort) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm. 12. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery) 13. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis 14. Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease 15. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. (Please see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a comprehensive list of agents that prolong the QT interval) 16. Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) male or female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential) 17. Known diagnosis of human deficiency virus (HIV) infection (HIV testing is not mandatory) 18. Patient with a history of another malignancy that is currently clinically significant or currently requires active intervention 19. Patients unwilling or unable to comply with the protocol.
|
|
E.5 End points |
E.5.1 | Primary end point(s) | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |